SanBio Company Limited (4592.T)
JPY 762.0
(-4.87%)
JPY 762.0
(-4.87%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 665 Million JPY | -28.72% |
| 2022 | 933 Million JPY | -63.05% |
| 2021 | 2.52 Billion JPY | -36.88% |
| 2020 | 4 Billion JPY | 0.0% |
| 2019 | 4 Billion JPY | -0.83% |
| 2018 | 4.03 Billion JPY | 75.36% |
| 2017 | 2.3 Billion JPY | 76.92% |
| 2016 | 1.3 Billion JPY | 8.33% |
| 2015 | 1.2 Billion JPY | 0.0% |
| 2014 | 1.2 Billion JPY | 0.0% |
| 2013 | - JPY | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 598 Million JPY | -10.08% |
| 2024 Q2 | 531 Million JPY | -11.2% |
| 2023 Q2 | 799 Million JPY | -7.74% |
| 2023 Q4 | 665 Million JPY | -9.15% |
| 2023 FY | 665 Million JPY | -28.72% |
| 2023 Q1 | 866 Million JPY | -7.18% |
| 2023 Q3 | 732 Million JPY | -8.39% |
| 2022 Q4 | 933 Million JPY | -6.7% |
| 2022 Q3 | 1 Billion JPY | -56.52% |
| 2022 FY | 933 Million JPY | -63.05% |
| 2022 Q2 | 2.3 Billion JPY | -37.84% |
| 2022 Q1 | 3.7 Billion JPY | 46.53% |
| 2021 FY | 2.52 Billion JPY | -36.88% |
| 2021 Q4 | 2.52 Billion JPY | -31.76% |
| 2021 Q2 | 3.7 Billion JPY | -7.5% |
| 2021 Q1 | 4 Billion JPY | 0.0% |
| 2021 Q3 | 3.7 Billion JPY | 0.0% |
| 2020 Q2 | 4 Billion JPY | 0.0% |
| 2020 FY | 4 Billion JPY | 0.0% |
| 2020 Q4 | 4 Billion JPY | 0.0% |
| 2020 Q3 | 4 Billion JPY | 0.0% |
| 2020 Q1 | 4 Billion JPY | 0.0% |
| 2019 FY | 4 Billion JPY | -0.83% |
| 2019 Q3 | 4 Billion JPY | 0.0% |
| 2019 Q4 | 4 Billion JPY | 0.0% |
| 2019 Q2 | 4 Billion JPY | -0.42% |
| 2019 Q1 | 4.01 Billion JPY | -0.41% |
| 2018 FY | 4.03 Billion JPY | 75.36% |
| 2018 Q4 | 4.03 Billion JPY | 46.67% |
| 2018 Q3 | 2.75 Billion JPY | -0.6% |
| 2018 Q2 | 2.76 Billion JPY | -0.6% |
| 2018 Q1 | 2.78 Billion JPY | 21.01% |
| 2017 Q1 | 2.35 Billion JPY | 80.77% |
| 2017 FY | 2.3 Billion JPY | 76.92% |
| 2017 Q4 | 2.3 Billion JPY | -0.72% |
| 2017 Q3 | 2.31 Billion JPY | -0.71% |
| 2017 Q2 | 2.33 Billion JPY | -0.71% |
| 2016 Q2 | 800 Million JPY | -20.0% |
| 2016 FY | 1.3 Billion JPY | 8.33% |
| 2016 Q3 | 1.5 Billion JPY | 87.5% |
| 2016 Q1 | 1 Billion JPY | -16.67% |
| 2016 Q4 | 1.3 Billion JPY | -13.33% |
| 2015 Q2 | 1.2 Billion JPY | 0.0% |
| 2015 Q1 | 1.2 Billion JPY | 0.0% |
| 2015 Q4 | 1.2 Billion JPY | 0.0% |
| 2015 FY | 1.2 Billion JPY | 0.0% |
| 2015 Q3 | 1.2 Billion JPY | 0.0% |
| 2014 FY | 1.2 Billion JPY | 0.0% |
| 2014 Q4 | 1.2 Billion JPY | 0.0% |
| 2013 FY | - JPY | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 2.46 Billion JPY | 73.074% |
| PRISM BioLab Co.,LTD | - JPY | -Infinity% |
| GNI Group Ltd. | 3.69 Billion JPY | 82.024% |
| Linical Co., Ltd. | 3 Billion JPY | 77.847% |
| Trans Genic Inc. | 2.25 Billion JPY | 70.537% |
| MEDINET Co., Ltd. | 2.3 Million JPY | -28725.314% |
| Soiken Holdings Inc. | - JPY | -Infinity% |
| Cytori Cell Research Institute, Inc. | 2.47 Billion JPY | 73.096% |
| AnGes, Inc. | 362.67 Million JPY | -83.36% |
| OncoTherapy Science, Inc. | 106.84 Million JPY | -522.374% |
| Nxera Pharma Co., Ltd. | 73.97 Billion JPY | 99.101% |
| Immuno-Biological Laboratories Co., Ltd. | 235.98 Million JPY | -181.801% |
| NanoCarrier Co., Ltd. | 1.1 Billion JPY | 40.032% |
| Carna Biosciences, Inc. | 182.97 Million JPY | -263.446% |
| CanBas Co., Ltd. | - JPY | -Infinity% |
| D. Western Therapeutics Institute, Inc. | 885.12 Million JPY | 24.869% |
| RaQualia Pharma Inc. | 367.71 Million JPY | -80.845% |
| Chiome Bioscience Inc. | 291 Million JPY | -128.522% |
| Kidswell Bio Corporation | 2.57 Billion JPY | 74.175% |
| PeptiDream Inc. | 22.79 Billion JPY | 97.083% |
| Oncolys BioPharma Inc. | 315.17 Million JPY | -110.997% |
| Ribomic Inc. | - JPY | -Infinity% |
| Healios K.K. | 4.53 Billion JPY | 85.327% |
| BrightPath Biotherapeutics Co., Ltd. | 112.5 Million JPY | -491.111% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 142.85 Million JPY | -365.513% |
| Delta-Fly Pharma, Inc. | - JPY | -Infinity% |
| StemRIM | - JPY | -Infinity% |
| CellSource Co., Ltd. | 97.54 Million JPY | -581.758% |
| FunPep Company Limited | - JPY | -Infinity% |
| Kringle Pharma, Inc. | - JPY | -Infinity% |
| Stella Pharma Corporation | 933.3 Million JPY | 28.747% |
| TMS Co., Ltd. | - JPY | -Infinity% |
| Noile-Immune Biotech Inc. | - JPY | -Infinity% |
| Cuorips Inc. | - JPY | -Infinity% |
| K Pharma,Inc. | - JPY | -Infinity% |
| Takara Bio Inc. | 968 Million JPY | 31.302% |
| ReproCELL Incorporated | - JPY | -Infinity% |
| PhoenixBio Co., Ltd. | 723.93 Million JPY | 8.14% |
| StemCell Institute Inc. | 8.78 Million JPY | -7470.583% |
| Japan Tissue Engineering Co., Ltd. | - JPY | -Infinity% |
| CellSeed Inc. | 151.25 Million JPY | -339.669% |